Ligand-induced regulation of glucagon-like peptide-I receptor function and expression in insulin-secreting β cells

Pancreas

Volumn 13, Issue 3, 1996, Pages 273-282

  Fehmann, Hans Christoph ^a   Jiang, Jiwen ^a   Pitt, David ^a   Schweinfurth, Johannes ^a   Göke, Burkhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cyclic AMP; Desensitization; Down regulation; Forskolin; G proteins; GLP I; GLP I receptor; Glucagon like peptide (GLP); Protein kinase A

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; GLUCAGON LIKE PEPTIDE 1; GUANINE NUCLEOTIDE BINDING PROTEIN; HORMONE RECEPTOR; INSULIN; LIGAND;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION;

EID: 0029798719     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199610000-00010     Document Type: Article

References (58)

1. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol 1964;24:1076-82.
2. Perley MJ, Kipnis DM. Plasma insulin responses to rat and intravenous glucose: studies in normal man and diabetic subjects. J Clin Invest 1967;46:1954-62.
3. La Barre J. Sur les possibilities d'un traitement du diabets oar L'incretine. Bull Acad Roy Med Belg 1932;12:620-34.
4. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969;123:261-6.
5. Nauck MA, Busing M, Orskov C, et al. Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated with combined heterotopic pancreas and kidney transplantation. Acta Diabetol 1993;30:39-45.
6. Fehmann HC, Göke R, Göke B. Glucagon-like peptide-I (7-37)/(7-36) amide is a new incretin. Mol Cell Endocrinol 1992;85:C39-44.
7. Ebert R, Creutzfeldt W. Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. Endocrinology 1982;111:1601-6.
8. Ebert R, Unger H, Creutzfeldt W. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia 1983;24:44-54.
9. Kolligs F, Fehmann HC, Göke R, Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995;44:16-9.
10. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-I (7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912-7.
11. Fehmann HC, Göke B, Göke R, Trautmann ME, Arnold R. Synergistic stimulatory effect of glucagon-like peptide-1 (36) amide and glucose-dependent insulinotropic polypeptide on the endocrine pancreas. FEBS Lett 1989;252:109-12.
12. Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36) amide receptor of insulin secreting cells. J Biol Chem 1993;268:19650-5.
13. Fehmann HC, Jiang J, Schweinfurth J, Wheeler MB, Boyd AE III, Göke B. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I (7-36)-amide, oxyntomodulin, exendin-4 and exendin (9-39). Peptides 1994;15:453-6.
14. Eng J, Kleinman WA, Singh L, Singh G, Raugman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from heloderma suspectum venom. J Biol Chem 1992; 267:7402-5.
15. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in βTC-1 insulinoma cells. Endocrinology 1992;130:159-66.
16. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes. N Engl J Med 1992;326:1316-22.
17. Nauck MA, Heimesaat MM, Oskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 (GLP-I) (7-36) amide but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with type 2 diabetes mellitus. J Clin Invest 1993;30:301-7.
18. Amiel SA. Glucagon-like peptide-I: a therapeutic glimmer. Lancet 1994;343:4-5.
19. Göke R, Cole T, Conlon JM. Characterization of the receptor for glucagon-like peptide-I (7-36) amide on plasma membranes from rat insulinoma-derived cells by covalent cross-linking. J Mol Endocrinol 1989;2:93-8.
20. Lankat-Buttgereit B, Göke R, Stöckmann F, Jiang J, Fehmann HC, Göke B. Detection of the human glucagon-like peptide I (7-36) amide receptor on insulinoma-derived cell membranes. Digestion 1994;55:29-33.
21. Van Eyll B, Lankat-Buttgereit B, Bode HP, Göke R, Göke B. Signal transduction of the GLP-I receptor cloned from a human insulinoma. FEBS Lett 1994;348:7-13.
22. Dillon JS, Tanizawa Y, Wheeler MB, et al. Cloning and functional expression of the human glucagon-like peptide-I (GLP-I) receptor. Endocrinology 1993;133:1907-10.
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
24. Göke R, Conlon JM. Receptors for glucagon-like peptide-I (7-36) amide on rat insulinoma-derived cells. J Endocrinol 1988;116:357-62.
25. 2-adrenergic receptor desensitization. Delineation with specific inhibitors. J Biol Chem 1990;265: 3202-9.
26. Gros L, Thorens B, Bataille D, Kervran A. Glucagon-like peptide-I (7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 1993;133:631-8.
27. Mayo E. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol 1992;6:1724-34.
28. Usdin TB, Mezay E, Button DC, Brownstein MJ, Bonner TL. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993;133:2861-70.
29. Jüppner H, Abou-Samra AB, Freeman M, et al. A G-protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991;254:1024-6.
30. Lok S, Kuijper JL, Jelinkek LJ, et al. The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. Gene 1994;140:203-9.
31. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning of the signal: desensitization of β-adrenergic receptor function. FASEB J 1990;4:2881-2889.
32. Fehmann HC, Habener JF. Homologous desensitization of the insulinotropic glucagon-like peptide-I (7-37) receptor on insulinoma (HIT T-15) cells. Endocrinology 1991;128: 2880-8.
33. Benovic JL, Strasser RH, Caron MG, Lefkowitz RJ. β-Adrenergic receptor kinase: Identification of a novel protein kinase which phosphorylates the agonist-occupied form of the receptor. Proc Natl Acad Sci USA 1986;83:2797-801.
34. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RI. β-Arrestin: a protein that regulates β-adrenergic receptor function. Science 1990;248:1547-50.
35. Lohse MJ, Andexinger S, Pitcher J, et al. Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specifity of beta-arrestin and arrestin in the beta-1 adrenergic receptor and rhodopsin systems. J Biol Chem 1992;267:8558-64.
36. Thorens B. Expression cloning of the pancreatic β-cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992;89:8641-5.
37. 2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation. Cell 1991;67:723-30.
38. Tobin AB, Keys B, Nohorski SR. Phosphorylation of a phosphoinositidase C-linked muscarinic receptor by a novel kinase distinct from β-adrenergic receptor kinase. FEBS Lett 1993;335:353-7.
39. Hadcock JR, Malbon CC. Down-regulation of β-adrenergic receptor: agonist-induced reduction in mRNA levels. Proc Natl Acad Sci USA 1988;85:5021-5.
40. 3-adrenergic receptor. J Biol Chem 1994;269:13148-55.
41. Akamizu T, Ikuyama S, Saji M, et al. Cloning, chromosomal assignment, and regulation of the rat thyrotropin receptor: expression of the gene is regulated by thyrotropin, agents that increase cAMP levels, and thyroid autoantibodies. Proc Natl Acad Sci USA 1990;87:5677-81.
42. Wang SZ, Hu J, Long RM, Pou W, Forray C, El-Fakahany EE. Agonist-induced down-regulation of ml muscarinic receptors and reduction of their mRNA level in a transfected cell line. FEBS Lett 1990;276:185-8.
43. Fukamauchi F, Hough C, Chuang DM. Expression and agonist-induced down-regulation of mRNAs of m2- and m3 muscarinic acetylcholine receptors in cultured cerebellar granule cells. J Neurochem 1991;56:716-9.
44. 2-adrenergic receptor. J Biol Chem 1989;264:16786-92.
45. Fujimoto J, Narayanan CS, Benjamin JE, Heinflink M, Gershengorn MC. Mechanism of thyrotropin-releasing hormone receptor messenger ribonucleic acid in stably transfected rat pituitary cells. Endocrinology 1992;130:1879-84.
46. 3 cells. J Biol Chem 1992;267:17296-303.
47. 3-adrenoreceptor messenger ribonucleic acids in adipose tissue. Endocrinology 1992;130:109-14.
48. 3-adrenergic receptor expression via multiple cAMP response elements. Proc Natl Acad Sci USA 1992;89:4490-4.
49. Urena P, Ilda-Klein A, Kong XF, et al. Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17/2.8 and OK cells. Endocrinology 1994;134:451-6.
50. 2A-adrenergic receptor gene by cAMP: evidence for multiple cAMP responsive sequences in the promoter region of this gene. Cell Signal 1994;6:73-82.
51. Clark AR, Docherty K. Negative regulation of transcription in eukaryotes. Biochem J 1993;296:521-41.
52. McCuaig KA, Clarke JC, White JH. Molecular cloning of the gene encoding the mouse parathyroid hormone/parathyroid hormone related peptide receptor. Proc Natl Acad Sci USA 1994;91:5051-5.
53. Göke R, Richter G, Göke B, Trautmann ME, Arnold R. Internalization of glucagon-like peptide-I (7-36) amide in rat insulinoma cells. Res Exp Med 1989;189:257-64.
54. Widman C, Dolci W. Thorens B. Agonist-induced internalization and recycling of the glucagon-like peptide-I receptor. Diabetes 1994;43(Suppl 1):176A.
55. Strader CD, Sigal IS, Blake AD, et al. The carboxyl terminus of the hamster β-adrenergic receptor expressed in mouse L-cells is not required for receptor sequestration. Cell 1987;49:855-63.
56. Hausdorff WP, Bouvier M, O'Dowd BF, Irons GP, Caron MG, Lefkowitz RJ. Phosphorylation sites on two domains of the β2-adrenergic receptor are involved in distinct pathways of receptor desensitization. J Biol Chem 1989;264:12657-65.
57. Campbell PT, Hnatowich M, O'Dowd BF, Caron MG, Lefkowitz RJ, Hausdorff WP. Mutations of the human β3-adrenergic receptor that impair coupling to Gs interfere with receptor down-regulation but not sequestration. Mol Pharmacol 1991;39:192-8.
58. Moro O, Lameh J, Sadee W. Serine and theronine rich domain regulates internalization of muscarinic cholinergic receptors. J Biol Chem 1993;268:6862-5.